http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2880950-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72192b485edb2254e5fa13f023bd4de4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate | 2015-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b731dedfc11d2a723cd7bddea7b2b5b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66063fc68d7f52f01e9eabb1facce725 |
| publicationDate | 2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2880950-T3 |
| titleOfInvention | HIV antibody therapy as a substitute for treatment |
| abstract | PRO 140, wherein said PRO 140 comprises (i) two light chains, each light chain comprising the expression product of the plasmid designated pVK:HuPR0140-VK deposited under the ATCC deposit designation PTA-4097, and (ii) two light chains heavy chains, each heavy chain comprising the expression product of either the plasmid designated pVg4:HuPRO140 HG2-VH deposited under the ATCC deposit designation PTA-4098 or the plasmid designated pVg4:HuPR0140 (mut B+D+I)-VH deposited under ATCC Depository Designation PTA-4099, for use in the treatment of an HIV-1 infected subject where the subject is stable on combination antiretroviral therapy prior to initiation of substitution treatment monotherapy and in that PRO 140 is administered subcutaneously and weekly as replacement therapy monotherapy in an amount of 350 mg and virological failure is prevented for a period of time of at least eight weeks as a result of the use of l PRO 140. |
| priorityDate | 2014-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 180.